Immunological axis of berberine in managing inflammation underlying chronic respiratory inflammatory diseases

Chem Biol Interact. 2020 Feb 1:317:108947. doi: 10.1016/j.cbi.2020.108947. Epub 2020 Jan 20.

Abstract

Inflammatory responses play a remarkable role in the mechanisms of acute and chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis and lung cancer. Currently, there is a resurgence in the use of drugs from natural sources for various ailments as potent therapeutics. Berberine, an alkaloid prominent in the Chinese traditional system of medicine has been reported to exert therapeutic properties in various diseases. Nevertheless, the number of studies focusing on the curative potential of berberine in inflammatory diseases involving the respiratory system is limited. In this review, we have attempted to discuss the reported anti-inflammatory properties of berberine that function through several pathways such as, the NF-κB, ERK1/2 and p38 MAPK pathways which affect several pro-inflammatory cytokines in the pathophysiological processes involved in chronic respiratory diseases. This review would serve to provide valuable information to researchers who work in this field and a new direction in the field of drug discovery with respect to respiratory diseases.

Keywords: Asthma; Berberine; COPD; Inflammatory diseases; Lung cancer; Pulmonary fibrosis; Respiratory diseases.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Berberine / pharmacology*
  • Chronic Disease
  • Gene Expression Regulation / drug effects
  • Humans
  • Inflammation / drug therapy*
  • Respiratory Tract Diseases / drug therapy*

Substances

  • Anti-Inflammatory Agents
  • Berberine